Application developed for the evaluation of the loss of quality of life in children under 2 years with the Respiratory Syncytial Virus (RSV) and their families, through a questionnaire (SynciQ) conducted for the study “Needs for future pharmaco-economic analysis of Future vaccines against RSV: Estimation of disease burden and loss of quality of life. Prospective part. ” This questionnaire will be completed by the family members of the child on days 0 (when RSV infection is confirmed), 7 and 14 (disease follow-up evaluation) and 30 (considered as completed recovery).